{"name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","slug":"shanghai-hengrui-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"shanghaihengrui.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"SHR-8068 injection","genericName":"SHR-8068 injection","slug":"shr-8068-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Adebrelimab injection","genericName":"Adebrelimab injection","slug":"adebrelimab-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"Alomnertinib Mesilate","genericName":"Alomnertinib Mesilate","slug":"alomnertinib-mesilate","indication":"Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations","status":"phase_2"},{"name":"Paclitaxel, Docetaxel, Irinotecan","genericName":"Paclitaxel, Docetaxel, Irinotecan","slug":"paclitaxel-docetaxel-irinotecan","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-A1904","genericName":"SHR-A1904","slug":"shr-a1904","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"SHR-A1912","genericName":"SHR-A1912","slug":"shr-a1912","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"SHR-A2102 for Injection","genericName":"SHR-A2102 for Injection","slug":"shr-a2102-for-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"SHR6508 plus oral placebo tablets","genericName":"SHR6508 plus oral placebo tablets","slug":"shr6508-plus-oral-placebo-tablets","indication":"unknown","status":"phase_3"},{"name":"Sodium Chloride Physiological Solution","genericName":"Sodium Chloride Physiological Solution","slug":"sodium-chloride-physiological-solution","indication":"Fluid and electrolyte replacement in dehydration","status":"phase_3"},{"name":"Ametinib Mesylate Tablets","genericName":"Ametinib Mesylate Tablets","slug":"ametinib-mesylate-tablets","indication":"Other","status":"phase_2"},{"name":"BP102 Injection","genericName":"BP102 Injection","slug":"bp102-injection","indication":"Other","status":"phase_2"},{"name":"Dexmedetomidine Hydrochloride Nasal Spray","genericName":"Dexmedetomidine Hydrochloride Nasal Spray","slug":"dexmedetomidine-hydrochloride-nasal-spray","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"SHR-8068 injection","genericName":"SHR-8068 injection","slug":"shr-8068-injection","phase":"phase_3","mechanism":"SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"SHR6508 plus oral placebo tablets","genericName":"SHR6508 plus oral placebo tablets","slug":"shr6508-plus-oral-placebo-tablets","phase":"phase_3","mechanism":"SHR6508 is a small molecule drug that targets the molecular target.","indications":["unknown"],"catalyst":""},{"name":"Sodium Chloride Physiological Solution","genericName":"Sodium Chloride Physiological Solution","slug":"sodium-chloride-physiological-solution","phase":"phase_3","mechanism":"Sodium chloride physiological solution restores and maintains electrolyte balance and fluid homeostasis by providing isotonic saline replacement.","indications":["Fluid and electrolyte replacement in dehydration","Hypovolemia management","Maintenance of electrolyte balance during surgery or critical illness","Vehicle for intravenous drug administration"],"catalyst":""},{"name":"Adebrelimab injection","genericName":"Adebrelimab injection","slug":"adebrelimab-injection","phase":"phase_3","mechanism":"Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"Alomnertinib Mesilate","genericName":"Alomnertinib Mesilate","slug":"alomnertinib-mesilate","phase":"phase_2","mechanism":"Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.","indications":["Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations"],"catalyst":""},{"name":"Ametinib Mesylate Tablets","genericName":"Ametinib Mesylate Tablets","slug":"ametinib-mesylate-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BP102 Injection","genericName":"BP102 Injection","slug":"bp102-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dexmedetomidine Hydrochloride Nasal Spray","genericName":"Dexmedetomidine Hydrochloride Nasal Spray","slug":"dexmedetomidine-hydrochloride-nasal-spray","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paclitaxel, Docetaxel, Irinotecan","genericName":"Paclitaxel, Docetaxel, Irinotecan","slug":"paclitaxel-docetaxel-irinotecan","phase":"phase_3","mechanism":"Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division.","indications":["Non-small cell lung cancer","Ovarian cancer","Pancreatic cancer","Breast cancer"],"catalyst":""},{"name":"SHR-A1904","genericName":"SHR-A1904","slug":"shr-a1904","phase":"phase_3","mechanism":"SHR-A1904 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"SHR-A1912","genericName":"SHR-A1912","slug":"shr-a1912","phase":"phase_3","mechanism":"SHR-A1912 is a small molecule targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"SHR-A2102 for Injection","genericName":"SHR-A2102 for Injection","slug":"shr-a2102-for-injection","phase":"phase_3","mechanism":"SHR-A2102 for Injection is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxQVF9VRHN5WHZRLXI1dG1SQ2dIQ2hXTUNSOExGcmd6V1l0ZkswV1RCY2lsanpHMjk4bFdVSk9hU3lHWmxyVkJxejlKLXlWaGg5bTVKR1UyS3ZjWEtGMkJkZ1dKZTBBaUlTTEZJRmNBRlJ6eGdKZFpVbFhjX3BOdFdEUm1Cb19IUjBJd2lxY1ZLQmxNcmZOaXZ3QjhueUcwMFJLVVFhdXoxZW9aZVlQaUItU1BLMkNhdzZ0ZmdPVlVCdF9mM2c1UENtU2ktNURBcmZoU2pBRTY4RG9PdTV5NXdQNkd6NkhXVWYyeDVNS3o4TXJwbTI3eE5QVE5sakRZMERHRF9Ya3A2a25PS2t4aGM2T0dqWm1zV0JwNk1JY3hhbnFWWUdFczRFUy1udXZ4UzFhSGVMVzlLVDBOaWI3dzhHcWZYRDJTcGpDcm9wX3JOWdIBzwJBVV95cUxQVF9VRHN5WHZRLXI1dG1SQ2dIQ2hXTUNSOExGcmd6V1l0ZkswV1RCY2lsanpHMjk4bFdVSk9hU3lHWmxyVkJxejlKLXlWaGg5bTVKR1UyS3ZjWEtGMkJkZ1dKZTBBaUlTTEZJRmNBRlJ6eGdKZFpVbFhjX3BOdFdEUm1Cb19IUjBJd2lxY1ZLQmxNcmZOaXZ3QjhueUcwMFJLVVFhdXoxZW9aZVlQaUItU1BLMkNhdzZ0ZmdPVlVCdF9mM2c1UENtU2ktNURBcmZoU2pBRTY4RG9PdTV5NXdQNkd6NkhXVWYyeDVNS3o4TXJwbTI3eE5QVE5sakRZMERHRF9Ya3A2a25PS2t4aGM2T0dqWm1zV0JwNk1JY3hhbnFWWUdFczRFUy1udXZ4UzFhSGVMVzlLVDBOaWI3dzhHcWZYRDJTcGpDcm9wX3JOWQ?oc=5","date":"2026-04-07","type":"trial","source":"The Manila Times","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - The Manila Times","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOaTBneEVHeFVJUUdFSnF0Vk9JTFgwVkJtbF9LdGw2ZEFQamY2dkNqbG1iSTNQbUNtenZocENud0RYemp3Nlh4UmNDckZESFh6dnNiQkFTV1ctbkZYMmJsNVY5SGhjVnV3RTh6SnRBeDN2U0xCcXgwVE5VSG9kcmFGR050WQ?oc=5","date":"2026-04-02","type":"pipeline","source":"BioWorld News","summary":"Hengrui discovers new Nav1.8 blockers - BioWorld News","headline":"Hengrui discovers new Nav1.8 blockers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1JSFpydFFMbFRuZnRJaUV1WjdxV20xQkJ3Nk5zZi1Kb1dXMGM2Vzc0ZDdUY0h6SXRCbzBvVFBtWE1qTUtzNVkyX0JTbEczVGRINkRZakNZVllncFNMOGszazdQTS0zVHZPOEwtMUg2ZDlNUQ?oc=5","date":"2026-03-26","type":"earnings","source":"Bayelsa Watch","summary":"Hengrui Pharma Full-Year 2025 Earnings: Revenue Hits RMB 31.63 Billion - Bayelsa Watch","headline":"Hengrui Pharma Full-Year 2025 Earnings: Revenue Hits RMB 31.63 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOdWJEZHA1ZVp5SGJ6SmNoNmJZcndMbGhFckVJM2hJZUpxSjZoU1Y0QXViQWZNM3ZRY0t1UzlSVTJFejZLWHFFNm5JRHBZSGR0NWhUbWlwWF9hN0VrOEcwSmJkX0xlRGVEUVROTEVUckR3SVFtYUVGa2tKb3dodzZBeGpnRm90cGZ3MEVTaGFyNHQ2aUNENzVBZGxGR2MxT2lFU2RGY3VYZmhtWTNfdHcyWHh2RWJGeEMway1jaVBhSU9vMDRDMHRQV3Bzb3FLZWlTVHJsYm9SLXF3elhEek1uUXFZNA?oc=5","date":"2026-03-24","type":"pipeline","source":"marketscreener.com","summary":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shanghai Shengdi Private Equity Fund Management Co., Ltd., Shenzhen Yingtai Asset Manag","headline":"Shanghai Ruihongdi Pharmaceutical Co., Ltd. announced that it expects to receive CNY 750 million in funding from Shangha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNMmpyZE5TMmRUM1YzcWRaMmREMVZZWDg5UWtsOUwyUmNnVXFOeUl5RGVEVGF6aUVtQ3Nnem5vVE1qUGtzTmxyNDAyVDI4cDREN2QwcEZXLUdPRmVOMzl1aVFNc3ltVF8yTWliNDNHaXVWXzBDX2Y0dE5WeTdKU01qQ0xuS0lMTVdSbFJ0Tw?oc=5","date":"2026-03-06","type":"patent","source":"BioWorld News","summary":"Hengrui patents relaxin receptor 1 agonists - BioWorld News","headline":"Hengrui patents relaxin receptor 1 agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOZ1llTFI5SGdCSTJtX2Z0M0ZXaXFZQXNOaFRLUnhaV3g5aFp4V3RCa0Z2T0J6eHUtS3JRMmxDdG9qMUxUb1d0b0VBOGpKSUczUzJSZUtWalRqckk3UUpxdEo2aXplY3MzZlpMaVRXc0g3TzdPSVlwcEJDNDRhTm9kak1wUVh3ZGdBM2lKd19TNmJTekNsOHVoNUhmNjd0VnV0NllkRg?oc=5","date":"2026-01-29","type":"patent","source":"BioWorld News","summary":"Hengrui Pharmaceuticals patent reports Nav1.8 channel blockers - BioWorld News","headline":"Hengrui Pharmaceuticals patent reports Nav1.8 channel blockers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5","date":"2025-07-28","type":"deal","source":"reuters.com","summary":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal - reuters.com","headline":"GSK, China's Jiangsu Hengrui strike $500 million drug-development deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9VRThrWERwUEJGTnMzSERyVUxMbzBSaHo5MGloVjUyTFpnM1pIX2NtenI4OXdrQWVKR1llcjkycTZZcGJMZ3ZFaFhDdGFOVk9aLTVsZ1NKTkI3UThFcllYcDktMUJPdE9qZHVfa0FBUWc?oc=5","date":"2025-05-23","type":"pipeline","source":"Law.asia","summary":"Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years - Law.asia","headline":"Hengrui raises HKD9.8bn in HK’s largest pharma IPO in 5 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxOWVQ4YTkyTTJsUWN3THdXRURKNzBVYllWMVNJZVhtcUVvRDZIN1V0MFJ2dDVNTllQZUFidkJiNC05MVd1VDQ2ZW91WWVzd1FjTnJYZ2hmWk1kWHotQ2NWdGZDY192MEl3VWZtOHBMNFVnVnBkRDZRZ0hZT0c1Mk0zQm9yb2l1bGJIT3lla1otZkhxMmNrOTlLUW5tNGdmUFEwdDg5YkpVQU5BMkV1VnBLS0R5UU1RM0VVbE1Lc04taWFaamZGeFBkZGJQTXQyREpvVGppbjNpbG9Kc1UtRlRpczQwa3JoZDdRZWJycmpkM0tYZU04XzFDSjgtRkpBMGE2cmo2SkxzclNHcDlKZExXS2JyOHphbGUycWtIRTAwWVJhanVub1J2TkpMdW53UlZ5d3lwY3JUUkpYWUNqOWZVRFBmTVF0ek5DeE93X1ROekJOOFZtOEVVbHAzV0ctZTNJWWdBTWdZbHA4SDR2?oc=5","date":"2025-04-02","type":"deal","source":"PR Newswire","summary":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusion of VIVJOA® (Oteseconazole) Capsules in the Chinese National Reimbursement Drug","headline":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Recognition for the Inclusio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOWDZpX21nMGlHNTJBeGwyb09jOF9PeEdJUlNXRkZ6SmtNdGJ3NDd5N2xiTy1jMUxwWE9Vakg0a1ZHYldEM1lldWwyQmI3SHFpNlhSMklyNmpZSkp3VHROaEJaTTU2R0NVRkZWWUtaTnVMVEw0dzZDVS0tOERXcHE4OWNINnZkN3ZpU0FVZFE4WjFxNVJrUGJYTmN4N09hR1hCMExFNTVOTUI2S1ZjSXdkTlRaYzlXZWdiQWVwcERPdmdDbEtpYnh5OVExUUgtSmZjSkREeXJPd2dkMGMwdW41Y1JmWTEzTzhhOHB4YkUtdjd6YV9sU2N5TVRXSDBObjBZX0pnWnZQM2JoME15MWk4alh5dVR3V1ZEbVdwdVAzYWx3UlBMSEoxWDI2aXBkcERDUUE?oc=5","date":"2024-12-29","type":"trial","source":"PR Newswire","summary":"IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire","headline":"IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Ta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOM2tBZ3d4Um9GSmFNUUN5UE9hSGFDSUhOYjR0bEdfVklYaWdka0JDZllvTjRqejdpUW5XbUF0Q1VlT0JJZGZ1OXF5Qk81NHRaS1dEMUtiaFg3RWJpQ0Y4aDRabC1qTEJ0b3BqY1lFTFp5a3JpQ28wS2xteEdyNzNacjlheEdCTFIxS3NaSm9YQUlnOUtWTmNBcFdtLTBGelk1Nmc3UFFLWUtpTnd1Q0o3MVlXV2NxTEplckpLMjlzeVRCMkVYVDk1YmFsbVNSaG9uaTNFNDlrcHJRbk0?oc=5","date":"2024-08-01","type":"deal","source":"BioPharma APAC","summary":"Medicilon and Hengrui Pharma Forge Strategic Partnership to Accelerate Preclinical Drug Development - BioPharma APAC","headline":"Medicilon and Hengrui Pharma Forge Strategic Partnership to Accelerate Preclinical Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1WN3hBRmg1WUp2bWRhZHhXQ2Zyc19KRXAxLWxtak96Q1BkaVJtenh3clI2WkwyaURVQXBLQXFBYURLcHBIUVNVaTFTTm5OMl9sLXVSb1RtY3JzbS0wc3RZWENzUEVrdDlONEhZVHBUWmRMTGlSWnBFWFRQSEM?oc=5","date":"2024-05-01","type":"pipeline","source":"jnm.snmjournals.org","summary":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics - jnm.snmjournals.org","headline":"Landscape of Nuclear Medicine in China and Its Progress on Theranostics","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":8,"phase_2":3,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}